Precigen (PGEN) shares plummeted 7.17% in Monday's trading session, following the company's announcement of a staggering $115,000 wholesale acquisition cost for a single vial of its drug Papzimeos. The steep price point has sent shockwaves through the market, leading to a significant sell-off of the biotechnology firm's stock.

The $115,000 per vial price tag has raised serious concerns among investors about Papzimeos' market viability and accessibility. This pricing strategy could face substantial resistance from insurance companies and patients alike, potentially limiting the drug's commercial success. Market analysts are questioning whether this high cost could severely impact Papzimeos' competitiveness, especially if more affordable alternative treatments are available.

As trading continues, all eyes remain on Precigen for any additional context or justification for Papzimeos' pricing. The company's ability to defend its pricing strategy and demonstrate the drug's value proposition will be crucial in potentially stabilizing the stock price. Investors will be closely monitoring any further announcements or guidance from Precigen regarding their commercialization plans for Papzimeos, which could significantly influence the stock's performance in the coming days.